# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000886163-18-000058
Filing Date
2018-04-30
Accepted
2018-04-30 16:22:19
Documents
5
Effectiveness Date
2018-04-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | proxynotice2018.htm | DEFA14A | 18969
2 |  | a02szebligandpharmaceuti001.jpg | GRAPHIC | 225041
3 |  | a02szebligandpharmaceuti002.jpg | GRAPHIC | 103067
4 |  | a02szicligandpharmaceuti001.jpg | GRAPHIC | 206421
5 |  | a02szicligandpharmaceuti002.jpg | GRAPHIC | 160119
| Complete submission text file | 0000886163-18-000058.txt |  | 964117

Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33093 | Film No.: 18790105
SIC: 2834 Pharmaceutical Preparations